期刊文献+

CXCR4 HIV-1抑制剂的设计合成及活性研究 被引量:1

Design,synthesis and activity evaluation of new anti-HIV-1 CXCR4 inhibitors
原文传递
导出
摘要 目的设计、合成一系列新型四氢喹啉-苄基或苯并咪唑多胺类化合物,作为潜在的靶向CXCR4辅助受体的新型抑制剂,并测定其抗HIV-1活性。方法组合HIV-1辅助受体CXCR4抑制剂三氮构效团与CCR5部分药效团,设计并合成一系列新化合物并经1H-NMR、MS表征,用HIV-1ⅢB病毒测定化合物抑制活性。结果与结论设计合成的10个目标化合物未见文献报道。活性测试结果显示,四氢喹啉-苯并咪唑多胺类化合物具有较好的抗HIV活性(IC50<1μmol/L),四氢喹啉-苄基多胺类化合物活性较差(IC50>8μmol/L)。 Objective To design and synthesize a series of new type four hydrogen quinoline-benzyl/benzimidazole amine derivatives as a potential new inhibitor targeting auxiliary receptor CXCR 4, and determine their inhibitory activities to HIV-1.Methods Based on HIV-1 receptor CXCR4 inhibitors containing three nitrogen structure-activity motif and CCR5 partial hydrophobic pharmacophore , a series of new compounds were designed , synthesized and characterized by 1 HNMR and MS.The inhibitory activities of these compounds were determined using HIV-1 IIIB virus.Results and Conclusion Ten target compounds are synthesized .Four hydrogen quinoline-benzimidazole amine derivatives exhibit good anti-HIV activity(IC50 &lt;1 μmol/L), but four hydrogen quinoline-benzyl amine compounds are less active ((IC50 &gt;8 μmol/L).
出处 《军事医学》 CAS CSCD 北大核心 2014年第8期602-607,共6页 Military Medical Sciences
基金 国家自然科学基金资助项目(81102373)
关键词 CXCR4 HIV-1 抑制剂 合成 活性 inhibitor synthesis activity
  • 相关文献

参考文献19

  • 1Mayaud C, Cadranel J. HIV in the lung from 1982 to 2013[J]. Rev Mal Respir, 2014, 31 (2) : 119 - 132.
  • 2Global Report:UNAIDS report on the global AIDS epidemic 2013 [ R]. WHO Library Cataloguing-in-Publication Data, 2013.
  • 3Erik DC. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV [ J]. Int J Antimicrob Agents, 2009,33(4) : 307 -320.
  • 4刘叔文,吴曙光,姜世勃.新型抗艾滋病药物——HIV进入抑制剂的研究进展[J].中国药理学通报,2005,21(9):1034-1040. 被引量:19
  • 5Haqqani AA, Tihon JC. Entry inhibitors and their use in the treatment of HIV-1 infection[J]. Antiviral Res, 2013, 98(2): 158 - 170.
  • 6Don P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavilable, and selective small-molecule inhibi- tor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity [ J ]. Antimicrob Agents Chemother, 2005, 49( 1 ) : 4721 -4732.
  • 7Caseiro MM, Nelson M, Diaz RS, et al. Vicriviroc plus opti- mized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection : final results of two randomized phase 111 triMs[J]. J Infect, 2012, 65(4) : 326 -335.
  • 8Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140) [ J]. Antimicrob Agents Chemother, 2008, 52 (3) : 858 - 865.
  • 9Erik DC. The bicyclam AMD3100 story[J]. Nat Rev Drug Dis- cov, 2003, 2(7) : 581 -587.
  • 10Lchiyama K, Yokoyama-Kumakura S, Tanaka Y, et al. A duo-denally absorbable CXC chemokine receptor 4 antagonist, KRH- 1636, exhibits a potent and selective anti-HIV-1 activity [ J]. Proc Natl Acad Sci USA, 2003, 100(7) : 4185 -4190.

二级参考文献24

  • 1DONG M X,ZHANG J,PENG X Q,et al.Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents [J].Eur J Med Chem.2010,45(9): 4096-4103.
  • 2ERIK D C.Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV[J].J Antimicrobial Agents,2009,33(4): 307-320.
  • 3DUMMOND J B,PATERSON K B,PECHA A L,et al.Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women [J].J Acuir Immune Defic Syndr,2009,51(5): 546-553.
  • 4SYUPPLE P A,BATCHELOR D V,CORLESS M,et al.An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl- 4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798) [J].J Med Chem,2011,54 (1): 67–77.
  • 5LENZ J C,ROCKSTROH J K.Vicriviroc,a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties,promises and challenges[J].Expert Opin Drug Metab Toxicol,2010,6(9): 1139-1150.
  • 6BABA M,TAKASHIMA K,MIYAKE H,et al.TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans[J].Antimicrob Agents Chemother,2005,49 (11) : 4584-4591.
  • 7IMAMURA S,ICHIKAWA T,NISHIKAWA Y,et al.Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent anti-HIV-1 activity[J].J Med Chem,2006,49(9): 2784-2793.
  • 8ESTE J A.TAK-779 (Takeda) [J].Curr Opin Investig Drugs,2001,2 (3): 354-356.
  • 9STRIZKI J M,TREMBLAY C,XU S,et al.Discovery and characterization of Vicriviroc (SCH417690),a CCR5 antagonist with potent activity against human immunodeficiency virus type 1[J].Antimicrob Agents Chemother,2005,49(12): 4911-4919.
  • 10PULLEY S.Chemokine Biology-Basic Research and Clinical Application[M].Germamy: Springerlink,2007: 145–163.

共引文献19

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部